Global AAV Vector Gene Therapy Market Growth 2026-2032
The global AAV Vector Gene Therapy market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
AAV (Adeno-Associated Virus) vector gene therapy is a gene therapy method that uses adeno-associated virus as a vector to deliver, express or repair specific genes in patients. AAV is a non-pathogenic, non-oncogenic virus that is widely used in gene therapy research and clinical trials.
United States market for AAV Vector Gene Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for AAV Vector Gene Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for AAV Vector Gene Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key AAV Vector Gene Therapy players cover uniQure, Roche, Novartis, BioMarin Pharmaceutical, Ferring Pharmaceuticals A/S, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “AAV Vector Gene Therapy Industry Forecast” looks at past sales and reviews total world AAV Vector Gene Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected AAV Vector Gene Therapy sales for 2026 through 2032. With AAV Vector Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AAV Vector Gene Therapy industry.
This Insight Report provides a comprehensive analysis of the global AAV Vector Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on AAV Vector Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global AAV Vector Gene Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AAV Vector Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AAV Vector Gene Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of AAV Vector Gene Therapy market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global AAV Vector Gene Therapy market?
What factors are driving AAV Vector Gene Therapy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do AAV Vector Gene Therapy market opportunities vary by end market size?
How does AAV Vector Gene Therapy break out by Type, by Application?
AAV (Adeno-Associated Virus) vector gene therapy is a gene therapy method that uses adeno-associated virus as a vector to deliver, express or repair specific genes in patients. AAV is a non-pathogenic, non-oncogenic virus that is widely used in gene therapy research and clinical trials.
United States market for AAV Vector Gene Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for AAV Vector Gene Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for AAV Vector Gene Therapy is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key AAV Vector Gene Therapy players cover uniQure, Roche, Novartis, BioMarin Pharmaceutical, Ferring Pharmaceuticals A/S, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “AAV Vector Gene Therapy Industry Forecast” looks at past sales and reviews total world AAV Vector Gene Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected AAV Vector Gene Therapy sales for 2026 through 2032. With AAV Vector Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AAV Vector Gene Therapy industry.
This Insight Report provides a comprehensive analysis of the global AAV Vector Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on AAV Vector Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global AAV Vector Gene Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AAV Vector Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AAV Vector Gene Therapy.
This report presents a comprehensive overview, market shares, and growth opportunities of AAV Vector Gene Therapy market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- AAV1
- AAV2
- AAV8
- Other
- Duchenne Dystrophy
- Hemophilia
- Retinal Diseases
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- uniQure
- Roche
- Novartis
- BioMarin Pharmaceutical
- Ferring Pharmaceuticals A/S
- CSL Behring LLC
- PTC Therapeutics, Inc.
- Pfizer Inc.
What is the 10-year outlook for the global AAV Vector Gene Therapy market?
What factors are driving AAV Vector Gene Therapy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do AAV Vector Gene Therapy market opportunities vary by end market size?
How does AAV Vector Gene Therapy break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global AAV Vector Gene Therapy Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for AAV Vector Gene Therapy by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for AAV Vector Gene Therapy by Country/Region, 2021, 2025 & 2032
2.2 AAV Vector Gene Therapy Segment by Type
2.2.1 AAV1
2.2.2 AAV2
2.2.3 AAV8
2.2.4 Other
2.2.5 AAV Vector Gene Therapy Sales by Type
2.2.5.1 Global AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
2.2.5.2 Global AAV Vector Gene Therapy Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global AAV Vector Gene Therapy Sale Price by Type (2021-2026)
2.3 AAV Vector Gene Therapy Segment by Application
2.3.1 Duchenne Dystrophy
2.3.2 Hemophilia
2.3.3 Retinal Diseases
2.3.4 Other
2.3.5 AAV Vector Gene Therapy Sales by Application
2.3.5.1 Global AAV Vector Gene Therapy Sale Market Share by Application (2021-2026)
2.3.5.2 Global AAV Vector Gene Therapy Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global AAV Vector Gene Therapy Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global AAV Vector Gene Therapy Breakdown Data by Company
3.1.1 Global AAV Vector Gene Therapy Annual Sales by Company (2021-2026)
3.1.2 Global AAV Vector Gene Therapy Sales Market Share by Company (2021-2026)
3.2 Global AAV Vector Gene Therapy Annual Revenue by Company (2021-2026)
3.2.1 Global AAV Vector Gene Therapy Revenue by Company (2021-2026)
3.2.2 Global AAV Vector Gene Therapy Revenue Market Share by Company (2021-2026)
3.3 Global AAV Vector Gene Therapy Sale Price by Company
3.4 Key Manufacturers AAV Vector Gene Therapy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers AAV Vector Gene Therapy Product Location Distribution
3.4.2 Players AAV Vector Gene Therapy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR AAV VECTOR GENE THERAPY BY GEOGRAPHIC REGION
4.1 World Historic AAV Vector Gene Therapy Market Size by Geographic Region (2021-2026)
4.1.1 Global AAV Vector Gene Therapy Annual Sales by Geographic Region (2021-2026)
4.1.2 Global AAV Vector Gene Therapy Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic AAV Vector Gene Therapy Market Size by Country/Region (2021-2026)
4.2.1 Global AAV Vector Gene Therapy Annual Sales by Country/Region (2021-2026)
4.2.2 Global AAV Vector Gene Therapy Annual Revenue by Country/Region (2021-2026)
4.3 Americas AAV Vector Gene Therapy Sales Growth
4.4 APAC AAV Vector Gene Therapy Sales Growth
4.5 Europe AAV Vector Gene Therapy Sales Growth
4.6 Middle East & Africa AAV Vector Gene Therapy Sales Growth
5 AMERICAS
5.1 Americas AAV Vector Gene Therapy Sales by Country
5.1.1 Americas AAV Vector Gene Therapy Sales by Country (2021-2026)
5.1.2 Americas AAV Vector Gene Therapy Revenue by Country (2021-2026)
5.2 Americas AAV Vector Gene Therapy Sales by Type (2021-2026)
5.3 Americas AAV Vector Gene Therapy Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AAV Vector Gene Therapy Sales by Region
6.1.1 APAC AAV Vector Gene Therapy Sales by Region (2021-2026)
6.1.2 APAC AAV Vector Gene Therapy Revenue by Region (2021-2026)
6.2 APAC AAV Vector Gene Therapy Sales by Type (2021-2026)
6.3 APAC AAV Vector Gene Therapy Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe AAV Vector Gene Therapy by Country
7.1.1 Europe AAV Vector Gene Therapy Sales by Country (2021-2026)
7.1.2 Europe AAV Vector Gene Therapy Revenue by Country (2021-2026)
7.2 Europe AAV Vector Gene Therapy Sales by Type (2021-2026)
7.3 Europe AAV Vector Gene Therapy Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa AAV Vector Gene Therapy by Country
8.1.1 Middle East & Africa AAV Vector Gene Therapy Sales by Country (2021-2026)
8.1.2 Middle East & Africa AAV Vector Gene Therapy Revenue by Country (2021-2026)
8.2 Middle East & Africa AAV Vector Gene Therapy Sales by Type (2021-2026)
8.3 Middle East & Africa AAV Vector Gene Therapy Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of AAV Vector Gene Therapy
10.3 Manufacturing Process Analysis of AAV Vector Gene Therapy
10.4 Industry Chain Structure of AAV Vector Gene Therapy
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 AAV Vector Gene Therapy Distributors
11.3 AAV Vector Gene Therapy Customer
12 WORLD FORECAST REVIEW FOR AAV VECTOR GENE THERAPY BY GEOGRAPHIC REGION
12.1 Global AAV Vector Gene Therapy Market Size Forecast by Region
12.1.1 Global AAV Vector Gene Therapy Forecast by Region (2027-2032)
12.1.2 Global AAV Vector Gene Therapy Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global AAV Vector Gene Therapy Forecast by Type (2027-2032)
12.7 Global AAV Vector Gene Therapy Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 uniQure
13.1.1 uniQure Company Information
13.1.2 uniQure AAV Vector Gene Therapy Product Portfolios and Specifications
13.1.3 uniQure AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 uniQure Main Business Overview
13.1.5 uniQure Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche AAV Vector Gene Therapy Product Portfolios and Specifications
13.2.3 Roche AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis AAV Vector Gene Therapy Product Portfolios and Specifications
13.3.3 Novartis AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 BioMarin Pharmaceutical
13.4.1 BioMarin Pharmaceutical Company Information
13.4.2 BioMarin Pharmaceutical AAV Vector Gene Therapy Product Portfolios and Specifications
13.4.3 BioMarin Pharmaceutical AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 BioMarin Pharmaceutical Main Business Overview
13.4.5 BioMarin Pharmaceutical Latest Developments
13.5 Ferring Pharmaceuticals A/S
13.5.1 Ferring Pharmaceuticals A/S Company Information
13.5.2 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Product Portfolios and Specifications
13.5.3 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Ferring Pharmaceuticals A/S Main Business Overview
13.5.5 Ferring Pharmaceuticals A/S Latest Developments
13.6 CSL Behring LLC
13.6.1 CSL Behring LLC Company Information
13.6.2 CSL Behring LLC AAV Vector Gene Therapy Product Portfolios and Specifications
13.6.3 CSL Behring LLC AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CSL Behring LLC Main Business Overview
13.6.5 CSL Behring LLC Latest Developments
13.7 PTC Therapeutics, Inc.
13.7.1 PTC Therapeutics, Inc. Company Information
13.7.2 PTC Therapeutics, Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
13.7.3 PTC Therapeutics, Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 PTC Therapeutics, Inc. Main Business Overview
13.7.5 PTC Therapeutics, Inc. Latest Developments
13.8 Pfizer Inc.
13.8.1 Pfizer Inc. Company Information
13.8.2 Pfizer Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
13.8.3 Pfizer Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Pfizer Inc. Main Business Overview
13.8.5 Pfizer Inc. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global AAV Vector Gene Therapy Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for AAV Vector Gene Therapy by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for AAV Vector Gene Therapy by Country/Region, 2021, 2025 & 2032
2.2 AAV Vector Gene Therapy Segment by Type
2.2.1 AAV1
2.2.2 AAV2
2.2.3 AAV8
2.2.4 Other
2.2.5 AAV Vector Gene Therapy Sales by Type
2.2.5.1 Global AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
2.2.5.2 Global AAV Vector Gene Therapy Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global AAV Vector Gene Therapy Sale Price by Type (2021-2026)
2.3 AAV Vector Gene Therapy Segment by Application
2.3.1 Duchenne Dystrophy
2.3.2 Hemophilia
2.3.3 Retinal Diseases
2.3.4 Other
2.3.5 AAV Vector Gene Therapy Sales by Application
2.3.5.1 Global AAV Vector Gene Therapy Sale Market Share by Application (2021-2026)
2.3.5.2 Global AAV Vector Gene Therapy Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global AAV Vector Gene Therapy Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global AAV Vector Gene Therapy Breakdown Data by Company
3.1.1 Global AAV Vector Gene Therapy Annual Sales by Company (2021-2026)
3.1.2 Global AAV Vector Gene Therapy Sales Market Share by Company (2021-2026)
3.2 Global AAV Vector Gene Therapy Annual Revenue by Company (2021-2026)
3.2.1 Global AAV Vector Gene Therapy Revenue by Company (2021-2026)
3.2.2 Global AAV Vector Gene Therapy Revenue Market Share by Company (2021-2026)
3.3 Global AAV Vector Gene Therapy Sale Price by Company
3.4 Key Manufacturers AAV Vector Gene Therapy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers AAV Vector Gene Therapy Product Location Distribution
3.4.2 Players AAV Vector Gene Therapy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR AAV VECTOR GENE THERAPY BY GEOGRAPHIC REGION
4.1 World Historic AAV Vector Gene Therapy Market Size by Geographic Region (2021-2026)
4.1.1 Global AAV Vector Gene Therapy Annual Sales by Geographic Region (2021-2026)
4.1.2 Global AAV Vector Gene Therapy Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic AAV Vector Gene Therapy Market Size by Country/Region (2021-2026)
4.2.1 Global AAV Vector Gene Therapy Annual Sales by Country/Region (2021-2026)
4.2.2 Global AAV Vector Gene Therapy Annual Revenue by Country/Region (2021-2026)
4.3 Americas AAV Vector Gene Therapy Sales Growth
4.4 APAC AAV Vector Gene Therapy Sales Growth
4.5 Europe AAV Vector Gene Therapy Sales Growth
4.6 Middle East & Africa AAV Vector Gene Therapy Sales Growth
5 AMERICAS
5.1 Americas AAV Vector Gene Therapy Sales by Country
5.1.1 Americas AAV Vector Gene Therapy Sales by Country (2021-2026)
5.1.2 Americas AAV Vector Gene Therapy Revenue by Country (2021-2026)
5.2 Americas AAV Vector Gene Therapy Sales by Type (2021-2026)
5.3 Americas AAV Vector Gene Therapy Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AAV Vector Gene Therapy Sales by Region
6.1.1 APAC AAV Vector Gene Therapy Sales by Region (2021-2026)
6.1.2 APAC AAV Vector Gene Therapy Revenue by Region (2021-2026)
6.2 APAC AAV Vector Gene Therapy Sales by Type (2021-2026)
6.3 APAC AAV Vector Gene Therapy Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe AAV Vector Gene Therapy by Country
7.1.1 Europe AAV Vector Gene Therapy Sales by Country (2021-2026)
7.1.2 Europe AAV Vector Gene Therapy Revenue by Country (2021-2026)
7.2 Europe AAV Vector Gene Therapy Sales by Type (2021-2026)
7.3 Europe AAV Vector Gene Therapy Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa AAV Vector Gene Therapy by Country
8.1.1 Middle East & Africa AAV Vector Gene Therapy Sales by Country (2021-2026)
8.1.2 Middle East & Africa AAV Vector Gene Therapy Revenue by Country (2021-2026)
8.2 Middle East & Africa AAV Vector Gene Therapy Sales by Type (2021-2026)
8.3 Middle East & Africa AAV Vector Gene Therapy Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of AAV Vector Gene Therapy
10.3 Manufacturing Process Analysis of AAV Vector Gene Therapy
10.4 Industry Chain Structure of AAV Vector Gene Therapy
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 AAV Vector Gene Therapy Distributors
11.3 AAV Vector Gene Therapy Customer
12 WORLD FORECAST REVIEW FOR AAV VECTOR GENE THERAPY BY GEOGRAPHIC REGION
12.1 Global AAV Vector Gene Therapy Market Size Forecast by Region
12.1.1 Global AAV Vector Gene Therapy Forecast by Region (2027-2032)
12.1.2 Global AAV Vector Gene Therapy Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global AAV Vector Gene Therapy Forecast by Type (2027-2032)
12.7 Global AAV Vector Gene Therapy Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 uniQure
13.1.1 uniQure Company Information
13.1.2 uniQure AAV Vector Gene Therapy Product Portfolios and Specifications
13.1.3 uniQure AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 uniQure Main Business Overview
13.1.5 uniQure Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche AAV Vector Gene Therapy Product Portfolios and Specifications
13.2.3 Roche AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis AAV Vector Gene Therapy Product Portfolios and Specifications
13.3.3 Novartis AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 BioMarin Pharmaceutical
13.4.1 BioMarin Pharmaceutical Company Information
13.4.2 BioMarin Pharmaceutical AAV Vector Gene Therapy Product Portfolios and Specifications
13.4.3 BioMarin Pharmaceutical AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 BioMarin Pharmaceutical Main Business Overview
13.4.5 BioMarin Pharmaceutical Latest Developments
13.5 Ferring Pharmaceuticals A/S
13.5.1 Ferring Pharmaceuticals A/S Company Information
13.5.2 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Product Portfolios and Specifications
13.5.3 Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Ferring Pharmaceuticals A/S Main Business Overview
13.5.5 Ferring Pharmaceuticals A/S Latest Developments
13.6 CSL Behring LLC
13.6.1 CSL Behring LLC Company Information
13.6.2 CSL Behring LLC AAV Vector Gene Therapy Product Portfolios and Specifications
13.6.3 CSL Behring LLC AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CSL Behring LLC Main Business Overview
13.6.5 CSL Behring LLC Latest Developments
13.7 PTC Therapeutics, Inc.
13.7.1 PTC Therapeutics, Inc. Company Information
13.7.2 PTC Therapeutics, Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
13.7.3 PTC Therapeutics, Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 PTC Therapeutics, Inc. Main Business Overview
13.7.5 PTC Therapeutics, Inc. Latest Developments
13.8 Pfizer Inc.
13.8.1 Pfizer Inc. Company Information
13.8.2 Pfizer Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
13.8.3 Pfizer Inc. AAV Vector Gene Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Pfizer Inc. Main Business Overview
13.8.5 Pfizer Inc. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. AAV Vector Gene Therapy Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. AAV Vector Gene Therapy Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of AAV1
Table 4. Major Players of AAV2
Table 5. Major Players of AAV8
Table 6. Major Players of Other
Table 7. Global AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 8. Global AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Table 9. Global AAV Vector Gene Therapy Revenue by Type (2021-2026) & ($ million)
Table 10. Global AAV Vector Gene Therapy Revenue Market Share by Type (2021-2026)
Table 11. Global AAV Vector Gene Therapy Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global AAV Vector Gene Therapy Sale by Application (2021-2026) & (K Units)
Table 13. Global AAV Vector Gene Therapy Sale Market Share by Application (2021-2026)
Table 14. Global AAV Vector Gene Therapy Revenue by Application (2021-2026) & ($ million)
Table 15. Global AAV Vector Gene Therapy Revenue Market Share by Application (2021-2026)
Table 16. Global AAV Vector Gene Therapy Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global AAV Vector Gene Therapy Sales by Company (2021-2026) & (K Units)
Table 18. Global AAV Vector Gene Therapy Sales Market Share by Company (2021-2026)
Table 19. Global AAV Vector Gene Therapy Revenue by Company (2021-2026) & ($ millions)
Table 20. Global AAV Vector Gene Therapy Revenue Market Share by Company (2021-2026)
Table 21. Global AAV Vector Gene Therapy Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers AAV Vector Gene Therapy Producing Area Distribution and Sales Area
Table 23. Players AAV Vector Gene Therapy Products Offered
Table 24. AAV Vector Gene Therapy Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global AAV Vector Gene Therapy Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global AAV Vector Gene Therapy Sales Market Share Geographic Region (2021-2026)
Table 29. Global AAV Vector Gene Therapy Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global AAV Vector Gene Therapy Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global AAV Vector Gene Therapy Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global AAV Vector Gene Therapy Sales Market Share by Country/Region (2021-2026)
Table 33. Global AAV Vector Gene Therapy Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global AAV Vector Gene Therapy Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas AAV Vector Gene Therapy Sales by Country (2021-2026) & (K Units)
Table 36. Americas AAV Vector Gene Therapy Sales Market Share by Country (2021-2026)
Table 37. Americas AAV Vector Gene Therapy Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 39. Americas AAV Vector Gene Therapy Sales by Application (2021-2026) & (K Units)
Table 40. APAC AAV Vector Gene Therapy Sales by Region (2021-2026) & (K Units)
Table 41. APAC AAV Vector Gene Therapy Sales Market Share by Region (2021-2026)
Table 42. APAC AAV Vector Gene Therapy Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 44. APAC AAV Vector Gene Therapy Sales by Application (2021-2026) & (K Units)
Table 45. Europe AAV Vector Gene Therapy Sales by Country (2021-2026) & (K Units)
Table 46. Europe AAV Vector Gene Therapy Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 48. Europe AAV Vector Gene Therapy Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa AAV Vector Gene Therapy Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa AAV Vector Gene Therapy Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa AAV Vector Gene Therapy Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of AAV Vector Gene Therapy
Table 54. Key Market Challenges & Risks of AAV Vector Gene Therapy
Table 55. Key Industry Trends of AAV Vector Gene Therapy
Table 56. AAV Vector Gene Therapy Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. AAV Vector Gene Therapy Distributors List
Table 59. AAV Vector Gene Therapy Customer List
Table 60. Global AAV Vector Gene Therapy Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global AAV Vector Gene Therapy Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas AAV Vector Gene Therapy Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas AAV Vector Gene Therapy Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC AAV Vector Gene Therapy Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC AAV Vector Gene Therapy Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe AAV Vector Gene Therapy Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe AAV Vector Gene Therapy Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa AAV Vector Gene Therapy Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa AAV Vector Gene Therapy Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global AAV Vector Gene Therapy Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global AAV Vector Gene Therapy Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global AAV Vector Gene Therapy Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global AAV Vector Gene Therapy Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. uniQure Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 75. uniQure AAV Vector Gene Therapy Product Portfolios and Specifications
Table 76. uniQure AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. uniQure Main Business
Table 78. uniQure Latest Developments
Table 79. Roche Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 80. Roche AAV Vector Gene Therapy Product Portfolios and Specifications
Table 81. Roche AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Roche Main Business
Table 83. Roche Latest Developments
Table 84. Novartis Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 85. Novartis AAV Vector Gene Therapy Product Portfolios and Specifications
Table 86. Novartis AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Novartis Main Business
Table 88. Novartis Latest Developments
Table 89. BioMarin Pharmaceutical Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 90. BioMarin Pharmaceutical AAV Vector Gene Therapy Product Portfolios and Specifications
Table 91. BioMarin Pharmaceutical AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. BioMarin Pharmaceutical Main Business
Table 93. BioMarin Pharmaceutical Latest Developments
Table 94. Ferring Pharmaceuticals A/S Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 95. Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Product Portfolios and Specifications
Table 96. Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Ferring Pharmaceuticals A/S Main Business
Table 98. Ferring Pharmaceuticals A/S Latest Developments
Table 99. CSL Behring LLC Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 100. CSL Behring LLC AAV Vector Gene Therapy Product Portfolios and Specifications
Table 101. CSL Behring LLC AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. CSL Behring LLC Main Business
Table 103. CSL Behring LLC Latest Developments
Table 104. PTC Therapeutics, Inc. Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 105. PTC Therapeutics, Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
Table 106. PTC Therapeutics, Inc. AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. PTC Therapeutics, Inc. Main Business
Table 108. PTC Therapeutics, Inc. Latest Developments
Table 109. Pfizer Inc. Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 110. Pfizer Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
Table 111. Pfizer Inc. AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Pfizer Inc. Main Business
Table 113. Pfizer Inc. Latest Developments
Table 1. AAV Vector Gene Therapy Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. AAV Vector Gene Therapy Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of AAV1
Table 4. Major Players of AAV2
Table 5. Major Players of AAV8
Table 6. Major Players of Other
Table 7. Global AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 8. Global AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Table 9. Global AAV Vector Gene Therapy Revenue by Type (2021-2026) & ($ million)
Table 10. Global AAV Vector Gene Therapy Revenue Market Share by Type (2021-2026)
Table 11. Global AAV Vector Gene Therapy Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global AAV Vector Gene Therapy Sale by Application (2021-2026) & (K Units)
Table 13. Global AAV Vector Gene Therapy Sale Market Share by Application (2021-2026)
Table 14. Global AAV Vector Gene Therapy Revenue by Application (2021-2026) & ($ million)
Table 15. Global AAV Vector Gene Therapy Revenue Market Share by Application (2021-2026)
Table 16. Global AAV Vector Gene Therapy Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global AAV Vector Gene Therapy Sales by Company (2021-2026) & (K Units)
Table 18. Global AAV Vector Gene Therapy Sales Market Share by Company (2021-2026)
Table 19. Global AAV Vector Gene Therapy Revenue by Company (2021-2026) & ($ millions)
Table 20. Global AAV Vector Gene Therapy Revenue Market Share by Company (2021-2026)
Table 21. Global AAV Vector Gene Therapy Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers AAV Vector Gene Therapy Producing Area Distribution and Sales Area
Table 23. Players AAV Vector Gene Therapy Products Offered
Table 24. AAV Vector Gene Therapy Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global AAV Vector Gene Therapy Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global AAV Vector Gene Therapy Sales Market Share Geographic Region (2021-2026)
Table 29. Global AAV Vector Gene Therapy Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global AAV Vector Gene Therapy Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global AAV Vector Gene Therapy Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global AAV Vector Gene Therapy Sales Market Share by Country/Region (2021-2026)
Table 33. Global AAV Vector Gene Therapy Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global AAV Vector Gene Therapy Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas AAV Vector Gene Therapy Sales by Country (2021-2026) & (K Units)
Table 36. Americas AAV Vector Gene Therapy Sales Market Share by Country (2021-2026)
Table 37. Americas AAV Vector Gene Therapy Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 39. Americas AAV Vector Gene Therapy Sales by Application (2021-2026) & (K Units)
Table 40. APAC AAV Vector Gene Therapy Sales by Region (2021-2026) & (K Units)
Table 41. APAC AAV Vector Gene Therapy Sales Market Share by Region (2021-2026)
Table 42. APAC AAV Vector Gene Therapy Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 44. APAC AAV Vector Gene Therapy Sales by Application (2021-2026) & (K Units)
Table 45. Europe AAV Vector Gene Therapy Sales by Country (2021-2026) & (K Units)
Table 46. Europe AAV Vector Gene Therapy Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 48. Europe AAV Vector Gene Therapy Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa AAV Vector Gene Therapy Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa AAV Vector Gene Therapy Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa AAV Vector Gene Therapy Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa AAV Vector Gene Therapy Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of AAV Vector Gene Therapy
Table 54. Key Market Challenges & Risks of AAV Vector Gene Therapy
Table 55. Key Industry Trends of AAV Vector Gene Therapy
Table 56. AAV Vector Gene Therapy Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. AAV Vector Gene Therapy Distributors List
Table 59. AAV Vector Gene Therapy Customer List
Table 60. Global AAV Vector Gene Therapy Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global AAV Vector Gene Therapy Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas AAV Vector Gene Therapy Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas AAV Vector Gene Therapy Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC AAV Vector Gene Therapy Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC AAV Vector Gene Therapy Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe AAV Vector Gene Therapy Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe AAV Vector Gene Therapy Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa AAV Vector Gene Therapy Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa AAV Vector Gene Therapy Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global AAV Vector Gene Therapy Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global AAV Vector Gene Therapy Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global AAV Vector Gene Therapy Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global AAV Vector Gene Therapy Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. uniQure Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 75. uniQure AAV Vector Gene Therapy Product Portfolios and Specifications
Table 76. uniQure AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. uniQure Main Business
Table 78. uniQure Latest Developments
Table 79. Roche Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 80. Roche AAV Vector Gene Therapy Product Portfolios and Specifications
Table 81. Roche AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Roche Main Business
Table 83. Roche Latest Developments
Table 84. Novartis Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 85. Novartis AAV Vector Gene Therapy Product Portfolios and Specifications
Table 86. Novartis AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Novartis Main Business
Table 88. Novartis Latest Developments
Table 89. BioMarin Pharmaceutical Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 90. BioMarin Pharmaceutical AAV Vector Gene Therapy Product Portfolios and Specifications
Table 91. BioMarin Pharmaceutical AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. BioMarin Pharmaceutical Main Business
Table 93. BioMarin Pharmaceutical Latest Developments
Table 94. Ferring Pharmaceuticals A/S Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 95. Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Product Portfolios and Specifications
Table 96. Ferring Pharmaceuticals A/S AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Ferring Pharmaceuticals A/S Main Business
Table 98. Ferring Pharmaceuticals A/S Latest Developments
Table 99. CSL Behring LLC Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 100. CSL Behring LLC AAV Vector Gene Therapy Product Portfolios and Specifications
Table 101. CSL Behring LLC AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. CSL Behring LLC Main Business
Table 103. CSL Behring LLC Latest Developments
Table 104. PTC Therapeutics, Inc. Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 105. PTC Therapeutics, Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
Table 106. PTC Therapeutics, Inc. AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. PTC Therapeutics, Inc. Main Business
Table 108. PTC Therapeutics, Inc. Latest Developments
Table 109. Pfizer Inc. Basic Information, AAV Vector Gene Therapy Manufacturing Base, Sales Area and Its Competitors
Table 110. Pfizer Inc. AAV Vector Gene Therapy Product Portfolios and Specifications
Table 111. Pfizer Inc. AAV Vector Gene Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Pfizer Inc. Main Business
Table 113. Pfizer Inc. Latest Developments
LIST OF FIGURES
Figure 1. Picture of AAV Vector Gene Therapy
Figure 2. AAV Vector Gene Therapy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global AAV Vector Gene Therapy Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global AAV Vector Gene Therapy Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. AAV Vector Gene Therapy Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. AAV Vector Gene Therapy Sales Market Share by Country/Region (2025)
Figure 10. AAV Vector Gene Therapy Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of AAV1
Figure 12. Product Picture of AAV2
Figure 13. Product Picture of AAV8
Figure 14. Product Picture of Other
Figure 15. Global AAV Vector Gene Therapy Sales Market Share by Type in 2026
Figure 16. Global AAV Vector Gene Therapy Revenue Market Share by Type (2021-2026)
Figure 17. AAV Vector Gene Therapy Consumed in Duchenne Dystrophy
Figure 18. Global AAV Vector Gene Therapy Market: Duchenne Dystrophy (2021-2026) & (K Units)
Figure 19. AAV Vector Gene Therapy Consumed in Hemophilia
Figure 20. Global AAV Vector Gene Therapy Market: Hemophilia (2021-2026) & (K Units)
Figure 21. AAV Vector Gene Therapy Consumed in Retinal Diseases
Figure 22. Global AAV Vector Gene Therapy Market: Retinal Diseases (2021-2026) & (K Units)
Figure 23. AAV Vector Gene Therapy Consumed in Other
Figure 24. Global AAV Vector Gene Therapy Market: Other (2021-2026) & (K Units)
Figure 25. Global AAV Vector Gene Therapy Sale Market Share by Application (2025)
Figure 26. Global AAV Vector Gene Therapy Revenue Market Share by Application in 2026
Figure 27. AAV Vector Gene Therapy Sales by Company in 2026 (K Units)
Figure 28. Global AAV Vector Gene Therapy Sales Market Share by Company in 2026
Figure 29. AAV Vector Gene Therapy Revenue by Company in 2026 ($ millions)
Figure 30. Global AAV Vector Gene Therapy Revenue Market Share by Company in 2026
Figure 31. Global AAV Vector Gene Therapy Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global AAV Vector Gene Therapy Revenue Market Share by Geographic Region in 2026
Figure 33. Americas AAV Vector Gene Therapy Sales 2021-2026 (K Units)
Figure 34. Americas AAV Vector Gene Therapy Revenue 2021-2026 ($ millions)
Figure 35. APAC AAV Vector Gene Therapy Sales 2021-2026 (K Units)
Figure 36. APAC AAV Vector Gene Therapy Revenue 2021-2026 ($ millions)
Figure 37. Europe AAV Vector Gene Therapy Sales 2021-2026 (K Units)
Figure 38. Europe AAV Vector Gene Therapy Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa AAV Vector Gene Therapy Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa AAV Vector Gene Therapy Revenue 2021-2026 ($ millions)
Figure 41. Americas AAV Vector Gene Therapy Sales Market Share by Country in 2026
Figure 42. Americas AAV Vector Gene Therapy Revenue Market Share by Country (2021-2026)
Figure 43. Americas AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Figure 44. Americas AAV Vector Gene Therapy Sales Market Share by Application (2021-2026)
Figure 45. United States AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC AAV Vector Gene Therapy Sales Market Share by Region in 2026
Figure 50. APAC AAV Vector Gene Therapy Revenue Market Share by Region (2021-2026)
Figure 51. APAC AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Figure 52. APAC AAV Vector Gene Therapy Sales Market Share by Application (2021-2026)
Figure 53. China AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 57. India AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe AAV Vector Gene Therapy Sales Market Share by Country in 2026
Figure 61. Europe AAV Vector Gene Therapy Revenue Market Share by Country (2021-2026)
Figure 62. Europe AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Figure 63. Europe AAV Vector Gene Therapy Sales Market Share by Application (2021-2026)
Figure 64. Germany AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 65. France AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 66. UK AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Application (2021-2026)
Figure 72. Egypt AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of AAV Vector Gene Therapy in 2026
Figure 78. Manufacturing Process Analysis of AAV Vector Gene Therapy
Figure 79. Industry Chain Structure of AAV Vector Gene Therapy
Figure 80. Channels of Distribution
Figure 81. Global AAV Vector Gene Therapy Sales Market Forecast by Region (2027-2032)
Figure 82. Global AAV Vector Gene Therapy Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global AAV Vector Gene Therapy Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global AAV Vector Gene Therapy Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global AAV Vector Gene Therapy Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global AAV Vector Gene Therapy Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of AAV Vector Gene Therapy
Figure 2. AAV Vector Gene Therapy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global AAV Vector Gene Therapy Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global AAV Vector Gene Therapy Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. AAV Vector Gene Therapy Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. AAV Vector Gene Therapy Sales Market Share by Country/Region (2025)
Figure 10. AAV Vector Gene Therapy Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of AAV1
Figure 12. Product Picture of AAV2
Figure 13. Product Picture of AAV8
Figure 14. Product Picture of Other
Figure 15. Global AAV Vector Gene Therapy Sales Market Share by Type in 2026
Figure 16. Global AAV Vector Gene Therapy Revenue Market Share by Type (2021-2026)
Figure 17. AAV Vector Gene Therapy Consumed in Duchenne Dystrophy
Figure 18. Global AAV Vector Gene Therapy Market: Duchenne Dystrophy (2021-2026) & (K Units)
Figure 19. AAV Vector Gene Therapy Consumed in Hemophilia
Figure 20. Global AAV Vector Gene Therapy Market: Hemophilia (2021-2026) & (K Units)
Figure 21. AAV Vector Gene Therapy Consumed in Retinal Diseases
Figure 22. Global AAV Vector Gene Therapy Market: Retinal Diseases (2021-2026) & (K Units)
Figure 23. AAV Vector Gene Therapy Consumed in Other
Figure 24. Global AAV Vector Gene Therapy Market: Other (2021-2026) & (K Units)
Figure 25. Global AAV Vector Gene Therapy Sale Market Share by Application (2025)
Figure 26. Global AAV Vector Gene Therapy Revenue Market Share by Application in 2026
Figure 27. AAV Vector Gene Therapy Sales by Company in 2026 (K Units)
Figure 28. Global AAV Vector Gene Therapy Sales Market Share by Company in 2026
Figure 29. AAV Vector Gene Therapy Revenue by Company in 2026 ($ millions)
Figure 30. Global AAV Vector Gene Therapy Revenue Market Share by Company in 2026
Figure 31. Global AAV Vector Gene Therapy Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global AAV Vector Gene Therapy Revenue Market Share by Geographic Region in 2026
Figure 33. Americas AAV Vector Gene Therapy Sales 2021-2026 (K Units)
Figure 34. Americas AAV Vector Gene Therapy Revenue 2021-2026 ($ millions)
Figure 35. APAC AAV Vector Gene Therapy Sales 2021-2026 (K Units)
Figure 36. APAC AAV Vector Gene Therapy Revenue 2021-2026 ($ millions)
Figure 37. Europe AAV Vector Gene Therapy Sales 2021-2026 (K Units)
Figure 38. Europe AAV Vector Gene Therapy Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa AAV Vector Gene Therapy Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa AAV Vector Gene Therapy Revenue 2021-2026 ($ millions)
Figure 41. Americas AAV Vector Gene Therapy Sales Market Share by Country in 2026
Figure 42. Americas AAV Vector Gene Therapy Revenue Market Share by Country (2021-2026)
Figure 43. Americas AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Figure 44. Americas AAV Vector Gene Therapy Sales Market Share by Application (2021-2026)
Figure 45. United States AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC AAV Vector Gene Therapy Sales Market Share by Region in 2026
Figure 50. APAC AAV Vector Gene Therapy Revenue Market Share by Region (2021-2026)
Figure 51. APAC AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Figure 52. APAC AAV Vector Gene Therapy Sales Market Share by Application (2021-2026)
Figure 53. China AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 57. India AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe AAV Vector Gene Therapy Sales Market Share by Country in 2026
Figure 61. Europe AAV Vector Gene Therapy Revenue Market Share by Country (2021-2026)
Figure 62. Europe AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Figure 63. Europe AAV Vector Gene Therapy Sales Market Share by Application (2021-2026)
Figure 64. Germany AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 65. France AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 66. UK AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa AAV Vector Gene Therapy Sales Market Share by Application (2021-2026)
Figure 72. Egypt AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries AAV Vector Gene Therapy Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of AAV Vector Gene Therapy in 2026
Figure 78. Manufacturing Process Analysis of AAV Vector Gene Therapy
Figure 79. Industry Chain Structure of AAV Vector Gene Therapy
Figure 80. Channels of Distribution
Figure 81. Global AAV Vector Gene Therapy Sales Market Forecast by Region (2027-2032)
Figure 82. Global AAV Vector Gene Therapy Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global AAV Vector Gene Therapy Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global AAV Vector Gene Therapy Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global AAV Vector Gene Therapy Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global AAV Vector Gene Therapy Revenue Market Share Forecast by Application (2027-2032)
